The reduction in price target by Mizuho might cause some investors to adjust their expectations for ACADIA Pharmaceuticals' stock value, potentially leading to short-term price fluctuations. However, the maintenance of a Buy rating suggests a continued positive outlook on the company, which could mitigate any negative impact from the lowered price target.